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correlations between IFN-a and the other parameters showed 
that IFN-a levels correlated positively with high levels o f  triglyc­
erides (P = .004) and with the wasting syndrome (P = 0.002), 
and correlated negatively with an elevated hematocrit (P = .04). 
Moreover, 6 (75%) of the 8 patients with wasting but only 18 
(25%) of the 71 patients without wasting had detectable levels o f  
IFN-a (P = 0.01). The mean (±SD) levels of IFN-a were 3.6 ±  
6.8 pg/mL and 1.6 ±  6.4 pg/mL, respectively, in patients with 
and without active opportunistic infections at the time of sam­
pling (ƒ> = NS).
Grunfeld and colleagues [3] also found high levels of IFN-a in 
HIV-infected patients and a strong correlation between IFN-a 
and hypertriglyceridemia in these patients. This is the first re­
port, to our knowledge, of a correlation between IFN-a and the 
wasting syndrome. Interferon has been shown to induce an­
orexia [4], and it might play an important role in the wasting 
syndrome of HIV-infected patients. In our study TNF-a does 
not appear to be strongly implicated in AIDS-related wasting. 
Moreover, repeated administration of TNF-a in animals does 
not induce cachexia [5], It is interesting that only eight of our 
patients had a wasting syndrome. Studies o f  the role of cytokines 
in the wasting syndrome should be conducted in greater num­
bers of HIV-infected patients. Patients should be matched to 
controls according to other factors such as opportunistic infec­
tions or CD4 lymphocyte count, and levels of both TN F-a and 
IFN-a should be measured.
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Active Human Herpesvirus 6 Infection in an Adolescent 
Male
Sir— A ctive infection with human herpes virus 6 (HHV-6) in 
immunocompetent adolescents and adults may be more com­
mon than is generally believed [I]. We describe a case o f  active 
HHV-6 infection in a healthy adolescent.
A 17-year-old male was admitted to Saint Jozef Hospital 
(Kerkrade, the Netherlands) for a high recurrent fever (spikes to 
39.5°C) and a generalized erythematous skin rash. Physical ex­
amination revealed bilateral conjunctivitis, tonsillar pharyngi­
tis, and cervical lymphadenitis. Jaundice and mild hepatomeg­
aly were also noted. The hemoglobin level was 14.1 g/dL. The 
following hematologic alterations that were associated with tox­
icity and that were consistent with the presence of an infectious 
disease were noted. The erythrocyte sedimentation rate was ele-
mal, and the results of hematologic and b iochem ical tests w e re  
within normal range.
The patient’s rash subsided during the w eek after adm ission , 
but with gradual desquamation, especially o n  the palms o f  h is  
hands and the bottoms o f  his feet. The p a t ien t  recovered u n ­
eventfully. Because of the patient’s sym ptom s, the differential 
diagnosis included a variety of infectious diseases. T h e  pa tien t  
did not have a history of travel outside o f  his ho m etow n  and th e  
surrounding regions. Histologic exam ination o f  a biopsy speci­
men o f  a cervical gland revealed a nonspecific inflam m atory  
process. Histochemical staining o f  the  biopsy specim en was n o t  
performed. Appropriate microbiological cu ltu res  and  paired s e ­
rological tests were performed for detection o f  the followint*
Q
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species; Toxoplasma gondii; adenovirus; m easles  virus; parain
vated (38 mm/h). The WBC count was 15,600/mm3 (8% band Auenzae virus; parvovirus B 19; rubella virus; hepatitis  A, B, or (. '
forms; 76% neutrophils, with Döhle’s bodies and toxic granula­
tion [both found in ~30% of neutrophils]; and 3% lympho­
cytes). The platelet count was 130,000/mm3, Hepatic dysfunc-
virus; and HIV. The results o f  these cultures a n d  serological tests 
were uninformative or negative. ELISAs for cytomegalovirus 
(CMV) and Epstein-Barr virus were negative for IgM, but CM V'
tion was evidenced by the significant increase in the levels of !§A was detected on day 58 o f  hospitalization. Serum  specimen
bilirubin and liver enzymes. Other clinical findings were nor-
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were tested by indirect immunofluorescence [ 1 ], which showed 
a significant rise in the titer o f  HHV-6 IgG ( the  liter was 1 ;2() on  
day 9 o f  hospitalization and 1:640 on day 18). H H V -6  IgM was 
detected on day 18 o f  hospitalization (titer, 1 :160) and  day 5<S 
(titer, 1:10), but it was not detected a t  a later d a te  (table 1 ). Six 
months after the patient initially presented, an ELISA for detec­
tion of HIV antibodies was negative.
Despite the absence of lymphocytosis, our  pa tien t 's  clinical 
picture resembled a recently published description o f  an acute
CID 1995:20 (April) Correspondence 1071
Table 1. Antibody titers for an immunocompetent adolescent with active HHV-6 infection.
Viral antibody
Titer o f antibody by day o f illness
9 18 58 150 170
HHV-6 lgG 1:20 1:640 1:1,280 1:1,280 1:640
HHV-6 IgM <1:10 1:160 10 <1:10 <1:10
CMV IgG (AU) >43 > 70 >1,500 >1,500 >1,500
CMV IgM •  * V 1 t f » « 1 •  t 1 1 1 4
CM V IgA < ♦ # « t u 4* • ♦ « « « «
EBV-VCA IgG/IgM <1:8 <1:8 <1:8 <1:8 <1:8
NOTE. AU = arbitrary laboratory units; EBV-VCA = Epstein-Barr virus viral capsid antigen;, . .  -  negative
HHV-6 infection [2]. Simultaneous rises in the titer of antibody 
to HHV-6 and CMV have been attributed to cross-reactivity [3], 
The delay in the rise of the titer o f  CMV antibody (compared 
with the rise in the titer of HHV-6 antibody) suggests a concomi­
tant reactivation of CMV. The absence o f  IgM and the presence 
o f  IgA are also consistent with reactivation o f  CMV [4].
Niederman et al. [1] described a mild spectrum o f  symptoms 
caused by HHV-6 infection in three adults who did not have 
fever but who had an HHV-6 IgM response, as was the case for 
our patient. However, it may be difficult to differentiate be­
tween a primary HHV-6 infection and a reactivation o f  HHV-6 
infection [5]. Almost 100% of individuals are seropositive for 
HHV-6 by the time they are 4 years old [2]. The percentage o f  
individuals who are seropositive for HHV-6 declines with age, 
presumably due to a loss of antibody that results in a level of 
antibody that cannot be detected.
Our patient’s illness may have been caused by a primary 
HHV-6 infection, by an exogenous reinfection by another vari­
an t of HHV-6, or by endogenous reactivation (we were not able 
to determine the cause of our patient’s illness after examining 
these three possibilities) [5], The likelihood o f  HHV-6 infection 
must be considered when searching for the origin of an acute 
exanthemous febrile disease in adolescents.
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Teicoplanin Selects for Staphylococcus aureus That Is 
Resistant to Vancomycin
S ir— We are currently experiencing an ongoing epidemic o f  in­
fection with multiply-resistant, methicillin-resistant strains of 
staphylococci in the United States and other countries [1-4], 
The cyclic glycopeptides, including vancomycin and teico­
planin, are thought to be the preferred therapeutic agents for 
serious infections caused by methicillin-resistant strains [51 or
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for serious staphylococcal infections occurring in patients aller­
gic to /3-lactam antibiotics. Teicoplanin, which i.s currently un­
dergoing clinical trials, is a member o f  the cyclic glycopeptide 
class and has already been marketed in Europe and may be 
marketed in the United States. Resistance to teicoplanin and 
vancomycin has already been reported for clinical isolates of 
coagulase-negative species of staphylococci such as Staphylococ­
cus h em al yticus
It is also known that teicoplanin therapy for serious infection 
caused by Staphylococcus aureus can result in emergence of 
strains resistant to teicoplanin; however, these strains remain 
susceptible to vancomycin [7]. We have carried out a prelimi­
nary characterization o f  a susceptible strain o 1’S, aureus and the 
teicoplanin-resistant derivative that emerged during teicoplanin 
therapy for endocarditis [8]. We showed that the resistant strain 
expresses a new membrane protein o f  ~ 3 5  kD in molecular 
weight, that it shows increased expression of the two polypep­
tides o f  penicillin-binding protein (PBP2), and that it is more 
susceptible to lysis by lysostaphin, an endopeptidase that
